We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO Says FDA Oversight of Off-Label Drug Promotion Is Not Systematic
GAO Says FDA Oversight of Off-Label Drug Promotion Is Not Systematic
August 1, 2008
The FDA takes an average of seven months from the time it begins drafting to issue regulatory letters asking drugmakers to cease violative off-label drug promotions — and companies cited for serious violations take an average of four months to act, according to a new government study.